Inflammation in atherosclerosis and implications for therapy

Circulation

Volumn 109, Issue 23 SUPPL., 2004, Pages

  Paoletti, Rodolfo ^a   Gotto Jr , Antonio M ^b   Hajjar, David P ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Atherosclerosis; C reactive protein; Coronary heart disease; Inflammation; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; FISH OIL; MEVINOLIN; OMEGA 3 FATTY ACID; OXIDIZED LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PRAVASTATIN; PROSTAGLANDIN SYNTHASE INHIBITOR; SIMVASTATIN; STATINE DERIVATIVE;

ATHEROSCLEROSIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIET THERAPY; DRUG MECHANISM; DRUG TARGETING; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; INFECTION; INFLAMMATION; ISCHEMIC HEART DISEASE; NONHUMAN; OXIDATIVE STRESS; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SECONDARY PREVENTION; STROKE; UNSTABLE ANGINA PECTORIS;

ACUTE-PHASE REACTION; ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTERIOSCLEROSIS; CARDIOTONIC AGENTS; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CHRONIC DISEASE; CYTOKINES; CYTOMEGALOVIRUS INFECTIONS; DIET; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INFLAMMATION; INFLUENZA, HUMAN; LIPOPROTEINS, LDL; MALE; MICE; NITRIC OXIDE; RANDOMIZED CONTROLLED TRIALS; VASCULITIS;

EID: 2942701875     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
2. Prescott SM, McIntyre TM, Zimmerman GA, et al. Molecular events in acute inflammation. Arterioscler Thromb Vasc Biol. 2002;22:727-733.
3. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340:115-126.
4. Shah PK. Plaque disruption and thrombosis: potential role of inflammation and infection. Cardiol Clin. 1999;17:271-281.
5. Farmer JA, Torre-Amione G. Atherosclerosis and inflammation. Curr Atheroscler Rep. 2000;4:92-98.
6. Carr A, McCall MR, Frei B. Oxidation of LDL by myeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection. Arterioscler Thromb Vasc Biol. 2000;20:1716-1723.
7. Bloodsworth A, O'Donnell VB, Freeman BA. Nitric oxide regulation of free radical- and enzyme-mediated lipid and lipoprotein oxidation. Arterioscler Thromb Vasc Biol. 2000;20:1707-1715.
8. Ehara S, Ueda M, Naruko T, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001;103:1955-1960.
9. Toshima S, Hasegawa A, Kurabayashi M, et al. Circulating oxidized low density lipoprotein levels: a biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol. 2000;20:2243-2247.
10. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7-22.
11. Steinberg D, Witztum JL. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation. 2002;105:2107-2111.
12. Navab M, Berliner JA, Subbanagounder G, et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol. 2001;21:481-488.
13. Van Lenten BJ, Navab M, Shih D, et al. The role of high-density lipoproteins in oxidation and inflammation. Trends Cardiovasc Med. 2001;11:155-161.
14. Prasad A, Zhu J, Halcox JPJ, et al. Predisposition to atherosclerosis by infections: role of endothelial dysfunction. Circulation. 2002;106:184-190.
15. Gattone M, Iacoviello L, Colombo M, et al. Chlamydia pneumoniae and cytomegalovirus seropositivity, inflammatory markers, and the risk of myocardial infarction at a young age. Am Heart J. 2001;142:633-640.
16. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000;321:199-204.
17. Van Lenten BJ, Wagner AC, Nayak DP, et al. High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection. Circulation. 2001;103:2283-2288.
18. Ikeda U, Ito T, Shimada K. Interleukin-6 and acute coronary syndrome. Clin Cardiol. 2001;24:701-704.
19. Mortensen RF. C-reactive protein, inflammation, and innate immunity. Immunol Res. 2001;24:163-176.
20. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001;103:1813-1818.
21. Ridker PM, Rifai N, Pfeffer MA, et al, for the Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 1998;98:839-844.
22. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
23. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959-1965.
24. Packard CJ, O'Reilly DS, Caslake MJ, et al, for the West of Scotland Coronary Prevention Study Group. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med. 2000;343:1148-1155.
25. Speidl WS, Graf S, Homykewycz S, et al. High-sensitivity C-reactive protein in the prediction of coronary events in patients with premature coronary artery disease. Am Heart J. 2002;144:449-455.
26. Mosca L. C-reactive protein: to screen or not to screen? N Engl J Med. 2002;347:1615-1617.
27. The Expert Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation. 2002;106:3143-3421.
28. Gómez-Gerique JA, Ros E, Oliván J, et al. Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis. 2002;162:245-251.
29. Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 2001;103:1933-1935.
30. Wiklund O, Mattsson-Hultén L, Hurt-Camejo E, et al. Effects of simvastatin and atorvastatin on inflammation markers in plasma. J Intern Med. 2002;251:338-347.
31. Plenge JK, Hernandez TL, Weil KM, et al. Simvastatin lowers C-reactive protein within 14 days, an effect independent of low-density lipoprotein cholesterol reduction. Circulation. 2002;106:1447-1452.
32. Taylor AJ, Kent SM, Flaherty PJ, et al. ARBITER: Arterial biology for the investigation of the treatment effects of reducing cholesterol. A randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation. 2002;106:1055-1060.
33. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: a randomized controlled trial. JAMA. 2001;285:1711-1718.
34. Kinlay S, Schwartz GG, Olsson AG, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003;108:1560-1566.
35. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE). A randomized trial and cohort study. JAMA. 2001;286:64-70.
36. Hernández-Presa MA, Martín-Ventura JL, Ortega M, et al. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis. 2002;160:49-58.
37. Halkin A, Keren G. Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease. Am J Med. 2002; 112:126-134.
38. Molavi B, Rasouli N, Mehta JL. Peroxisome proliferator-activated receptor ligands as antiatherogenic agents: panacea or another Pandora's box? J Cardiovasc Pharmacol Therapeut. 2002;7:1-8.
39. Burleigh ME, Babaev VR, Oates JA, et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation. 2002;105:1816-1823.
40. De Caterina R, Liao JK, Libby P. Fatty acid modulation of endothelial activation. Am J Clin Nutr. 2000;71(suppl):213S-223S.
41. Albert CM, Campos H, Stampfer MJ, et al. Blood levels of long-chain n-3 fatty acids and the risk for sudden death. N Engl J Med. 2002;346:1113-1118.
42. Hu FB, Bronner L, Willett WC, et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA. 2002;287:1815-1821.
43. Hajjar DP, Pomerantz KB. Signal transduction in atherosclerosis: integration of cytokines and the eicosanoid network. FASEB J. 1992;6:2933-2939.
44. Nicholson AC, Hajjar DP. Transforming growth factor-beta up-regulates low-density lipoprotein receptor-mediated cholesterol metabolism in vascular smooth muscle cells. J Biol Chem. 1992;267:25982-25987.
45. Hajjar DP, Haberland ME. Lipoprotein trafficking in vascular cells. J Biol Chem. 1997;272:22975-22978.